At a glance
- Originator Fournier Pharma
- Class Hormonal replacements
- Mechanism of Action DNA-directed RNA polymerase stimulants; Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Menopausal syndrome; Postmenopausal osteoporosis
Most Recent Events
- 30 Mar 2001 Discontinued-I for Menopausal syndrome in France (Transdermal)
- 30 Mar 2001 Discontinued-I for Postmenopausal osteoporosis in France (Transdermal)
- 21 Jun 2000 Ares-Serono is now called Serono